Meeting
2013 ASCO Annual Meeting
Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor.
Authors
Jeffrey R. Infante
Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN
Jeffrey R. Infante , John D. Powderly II, Howard A. Burris III, Muaiad Kittaneh , Jessica Houston Grice , James F Smothers , Sara Brett , Margaret E. Fleming , Rena May , Shannon Marshall , Martin Devenport , Stanley Pillemer , Drew M. Pardoll , Lieping Chen , Solomon Langermann , Patricia LoRusso
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Biomarkers and Correlative Studies from Immunotherapy Trials
Clinical Trial Registration Number
NCT01352884
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3044)
DOI
10.1200/jco.2013.31.15_suppl.3044
Abstract #
3044
Poster Bd #
14C
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A multicenter, phase II study of soluble LAG-3 (Eftilagimod Alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC).
First Author: Julio Antonio Peguero
Poster
2018 ASCO Annual Meeting
A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.
First Author: Sadhna Shankar
Poster
2017 ASCO Annual Meeting
Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA CD3 TCB) for the treatment of CEA-expressing solid tumors.
First Author: Ignacio Melero
Poster
2023 ASCO Annual Meeting
A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.
First Author: Miguel Angel Villalona-Calero